H1 Launches Gen AI Tool to Accelerate Clinical Trials

H1, a leading healthcare information source, unveiled GenosAI, a generative AI tool integrated into its clinical trial platform, Trial Landscape. GenosAI streamlines complex inquiries, aiding sponsors in finding new sites, assessing patient recruitment strategies, and analyzing competition. Deloitte estimates it can reduce drug discovery costs by 70%. GenosAI empowers clinical researchers with advanced data analysis, speeding up decision-making and improving efficiency. It draws insights from 490,000 trials, 25 million publications, 10 million healthcare providers, 240 million patients, and 11 billion claims, offering natural language query responses akin to ChatGPT. CEO Ariel Katz believes GenosAI will revolutionize clinical trials, boosting diversity and efficacy.

Medigy Insights

H1's GenosAI, a new AI tool embedded in its Trial Landscape platform, revolutionizes clinical research. GenosAI leverages advanced data analysis, aiming to reduce drug discovery costs by up to 70%. It streamlines site selection, fosters diversity, and enhances trial design. GenosAI taps into H1's vast healthcare database, using natural language processing to provide quick, reliable responses to complex queries. CEO Ariel Katz envisions GenosAI as a powerful tool for pharmaceutical companies, promising to improve clinical trial diversity and efficacy while ensuring data privacy and security.

Continue reading at hitconsultant.net

Make faster decisions with community advice

Using AI to Predict Population Needs

Dr. Aalpen Patel, Geisinger's Chair of Radiology and Medical Director of AI, discusses the strategic implementation of AI in both clinical and administrative healthcare settings. He sheds light on …

Posted Oct 6, 2023 Artificial Intelligence Population Health Clinical Communities Healthcare Innovation Employer Services